ArticleJournal of thoracic disease2026
Post-LVAD cognitive trajectories and determinants of non-improvement in end-stage heart failure.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cognitive impairment is common in patients with end-stage heart failure and may adversely affect self-management, treatment adherence, and clinical outcomes after left ventricular assist device (LVAD) implantation. Although LVAD support can improve systemic and cerebral perfusion, postoperative cognitive trajectories remain heterogeneous, and the factors associated with failure to improve are not well defined, particularly in Asian populations. This study aimed to characterize changes in cognitive function after LVAD implantation and to identify clinical, laboratory, echocardiographic, and neuroimaging determinants of cognitive non-improvement. Methods: This single-center retrospective cohort study included 56 patients who underwent LVAD implantation and completed the Montreal Cognitive Assessment (MoCA) before surgery and approximately 1 year after surgery. Demographic and clinical characteristics, laboratory parameters, including bilirubin, echocardiographic indices, including right ventricular fractional area change (RV FAC) and valvular status, and head computed tomography (CT) findings were analyzed. Changes in MoCA scores were assessed using a paired Results: Before LVAD implantation, 39 of 56 patients (69.6%) had a MoCA score <26, indicating a high prevalence of baseline cognitive impairment. Alcohol use was more frequent among patients with cognitive impairment. At approximately 1 year after implantation, 43 of 56 patients (76.8%) showed improved MoCA scores, and the overall MoCA score increased significantly from baseline (P<0.05). In univariable analysis, ischemic cardiomyopathy, lower RV FAC, higher bilirubin levels, incident ischemic lesions on head CT, and new-onset ≥mild aortic regurgitation were associated with cognitive non-improvement. In multivariable analysis, elevated bilirubin and new-onset ≥mild aortic regurgitation remained independently associated with cognitive non-improvement. Conclusions: Most patients with end-stage heart failure experienced significant cognitive improvement within 1 year after LVAD implantation, whereas approximately one quarter did not. Elevated bilirubin and new-onset ≥mild aortic regurgitation may help identify patients at increased risk of limited cognitive recovery and may support closer postoperative surveillance and earlier targeted intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.